Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small ...

A biotech that uses artificial intelligence to assist its drug discovery efforts has relocated its headquarters from New York ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

SAN FRANCISCO — While generative AI (AI) is being hailed as a game-changer as it sweeps the globe, the concept of “in silico medicine,” or computational medicine, is not exactly a new one.

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with ...

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results ...

Hong Kong’s Insilico Medicine has found a way to use AI and deep learning to design, synthesise and validate a novel drug candidate in 46 days – 15 times faster than the best pharma companies.

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration ...

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class ...

Insilico Medicine, a clinical stage biotech company powered by generative artificial intelligence (AI), is connecting biology, chemistry and clinical trials analysis using next-generation AI systems.

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug designed using generative AI, to treat idiopathic pulmonary ...